whether angiotensin receptor blockers increase cancer or cardiovascular risk
August 2010
See updated FDA information regarding ARBs/cancer and Olmesartan/CV risks
ARBs and cancer. A recent meta-analysis started a buzz that ARBs might lead to a small increased cancer risk...about 1 more case for every 143 patients using an ARB instead of placebo for 4 years.
One theory is that angiotensin might be involved in cell growth. ARBs increase free angiotensin by blocking its receptors.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote